Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis

Cong Dai^{1,*}
Meng Wang^{1,*}
Jun Lu^{2,*}
Zhiming Dai³
Shuai Lin¹
Pengtao Yang¹
Tian Tian¹
Xinghan Liu¹
Weili Min¹
Zhijun Dai¹

¹Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, ²Clinical Research Center, The First Affiliated Hospital of Xi'an Jiaotong University, ³Department of Anesthesia, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China

*These authors contributed equally to this work

Background: PD-L1 has been reported to be expressed in diverse human malignancies. However, the prognostic value of PD-L1 in digestive system cancers remains inconclusive. Therefore, we conducted this meta-analysis to evaluate the prognostic impact of PD-L1 expression in digestive system cancers.

Materials and methods: We searched the PubMed, Embase, and the Chinese National Knowledge Infrastructure for publications concerning PD-L1 expression in digestive system cancers. Correlations of PD-L1 expression level with overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) were analyzed.

Results: Finally, 32 studies with 7,308 patients were included. Our results show that PD-L1 expression was significantly associated with poorer OS (hazard ratio [HR]=1.44, 95% confidence interval [CI]=1.18–1.76, $P<0.001$), but not DFS (HR=0.91, 95% CI=0.61–1.37, $P=0.657$) or RFS (HR=1.27, 95% CI=0.75–2.14, $P=0.368$). Moreover, in the subgroup analysis, significant associations between PD-L1 expression and OS were found in Asians (HR=1.50, 95% CI=1.19–1.89, $P=0.001$), gastric cancer (HR=1.43, 95% CI=1.05–1.94, $P=0.021$), and pancreatic carcinoma (HR=2.64, 95% CI=1.78–3.93, $P<0.001$).

Conclusion: These results suggest that the expression of PD-L1 is associated with worse OS in digestive system cancers, especially in gastric cancer and pancreatic cancer. In addition, PD-L1 may act as a new parameter for predicting poor prognosis and a promising target for anticancer therapy in digestive system cancers.

Keywords: PD-L1, digestive system cancers, prognosis, meta-analysis

Introduction

Cancer is now the major cause of death in developed countries, and its incidence and mortality are increasing for several cancer types, among which the most fatal are liver and pancreatic cancer.¹ Liver and pancreatic cancer are digestive system cancers, which also includes esophageal cancer (EC), gastric cancer, biliary tract cancer, and colorectal cancer (CRC). Of all the cancers, digestive system cancers demonstrate the highest incidence and death rates.^{2,3} Recently, the development of multidisciplinary therapies has significantly improved treatment outcomes, but the overall prognosis for sufferers of digestive system cancers is still poor. Current research is increasingly focused on new immunotherapeutic strategies, which could be a major breakthrough in the field of cancer treatment.⁴ In addition, certain immunologic checkpoint markers have been reported in digestive system cancers, among which PD-L1 is the focus of studies.⁵

Correspondence: Zhijun Dai
Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, No 157, Xiwu Road, Xi'an City, Shanxi Province, People's Republic of China 710004
Tel +86 29 8767 9519
Email dzj0911@126.com

PD-L1, also known as CD274 and B7-H1, is a member of the B7 family of immune regulatory cell surface proteins.⁶ It is commonly upregulated in many different human tumors. The combination of PD-L1 with the receptor PD-1, which has been reported to form and maintain an immunosuppressive microenvironment by suppressing the proliferation of activated T-cells and inducing the apoptosis of T-cells, is considered to be an important immunological escape mechanism that increases the risk of neoplasia.^{7–10} In addition, immune checkpoint blockade using PD-L1 antibodies seems to be one of the most promising immunotherapy approaches.¹¹ Although anti-PD-L1 therapies are continuously developing, the prognostic value of PD-L1 is still unclear in various digestive system cancers.

There are many studies that demonstrate the relationship between PD-L1 and survival of patients with different digestive system cancers. But, the conclusions have not reached a consensus and most studies only focused on one cancer type, and did not make an assessment on digestive system cancers. Herein, we conducted a meta-analysis to assess the impact of PD-L1 on the prognosis of digestive system cancers.

Methods

This meta-analysis complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Literature search strategy

We searched the PubMed, Embase, and the Chinese National Knowledge Infrastructure databases (up to June 2016) to obtain the relevant articles. The following keywords were used: “PD-L1,” “B7-H1,” “CD274,” “digestive system cancer,” “colorectal neoplasms,” “esophageal neoplasms,” “gastric cancer,” “hepatocellular carcinomas,” “pancreatic carcinomas,” “biliary tract neoplasms,” and “prognosis.” We also searched the references of the included studies manually to identify relevant publications. Two authors (Cong Dai and Meng Wang) performed the search strategy, and discrepancies were discussed by all the researchers in the group meeting.

Inclusion and exclusion criteria

No language restrictions were applied. If different studies published by the same investigators have overlapping data, only the most complete one was included.

Studies were included if they fulfilled the following criteria: 1) all selected cancer cases were pathologically

confirmed; 2) studies evaluated the relationship of PD-L1 expression in digestive system cancer patients with detailed information of overall survival (OS), disease-free survival (DFS), or recurrence-free survival (RFS); and 3) the study provided a hazard ratio (HR) with the corresponding confidence interval (CI) or sufficient data to calculate it. Articles meeting the following criteria were excluded: 1) unrelated or duplicate publication; 2) nonhuman experiments were performed; 3) case series, case reports, reviews, or studies without original data; 4) crude data were not provided or HRs could not be calculated.

Data extraction

Two independent researchers (Zhiming Dai and Shuai Lin) extracted the detailed information of included studies with a standardized format. The results were compared, and all the researchers in the group meeting discussed the final decision in case of any discrepancy. The following information was collected: first author surname, year of publication, patient source, number of patients, tumor types, specimen types, method of detection, PD-L1 expression, median follow-up, prognostic outcomes, HR estimate, and HR with its 95% CI. If any of these data were not offered in the study, items were recorded as “–”.

Quality assessment

Methodological quality was assessed using the Newcastle–Ottawa Scale (NOS). The scale includes three domains: selection, comparability, and outcome assessment. Studies with a score of 6–9 were regarded as high quality. Two authors (Cong Dai and Meng Wang) independently graded each study, and all the researchers in the group met to make final decisions regarding any discrepancies.

Statistical analyses

The statistical analyses were performed with Stata 12.0 (StataCorp LP, College Station, TX, USA). We computed the pooled HR and its 95% CI to evaluate the relationship between the PD-L1 and the prognosis of patients with digestive system cancer. In addition, prognostic markers were classified into OS, DFS, and RFS. If HRs were provided explicitly in the studies, we used them directly. Otherwise, we calculated the HR from the Kaplan–Meier survival curve or with the available data using methods described by Parmar et al.¹² Data from the Kaplan–Meier survival curves were read by Engauge Digitizer version 4.1. The *Q* test and the *I*² test were used to evaluate the heterogeneity among studies. If heterogeneity was significant ($P < 0.1$ or $I^2 > 50\%$),

random-effects model was used.¹³ Otherwise, a fixed-effects Mantel–Haenszel model was applied.¹⁴ We further conducted subgroup analyses by ethnicity, tumor type, and HR estimate. Sensitivity analysis was performed by omitting individual studies to examine the reliability of the results. Meta-regression analysis was conducted to identify potential factors causing heterogeneity.¹⁵ Publication bias was assessed using Begg's test, Egger's test, and Begg's funnel plot.^{16,17}

Results

Characteristics of included studies

We initially identified a total of 343 studies using the search criteria listed earlier. As shown in Figure 1, 311 studies were excluded owing to irrelevance to the analysis or lack of the relevant data we needed, or because they were reviews, letters, or animal experiments. Finally, there were 32 studies included in this meta-analysis.^{18–49}

We have summarized the characteristics of the 32 studies in Table 1. Of the 32 publications, 30 assessed the relationship between PD-L1 and OS in patients with digestive system neoplasms. In addition, eight studies evaluated the relationship between PD-L1 and DFS, and three studies evaluated PD-L1 and RFS. Studies with a total of 7,308 patients, from China, Korea, Japan, the UK, Switzerland, and Germany, were enrolled. In addition, the number of patients in each study ranged from 40 to 1,420. To observe the status of PD-L1 in patients with different cancers, we categorized the cancers into CRC (six studies), EC (five studies), gastric cancer (13 studies), hepatocellular cancer (four studies), pancreatic

cancer (three studies), and extrahepatic bile duct cancer (one study). The median positive rate of PD-L1 was 49.6% (range 19.8%–84.8%). The median follow-up times ranged from 20.7 to 75 months. In addition, in methodological quality assessment, all of the studies, which obtained scores ranging from 6 to 9, were considered high quality (Table 1).

Main meta-analysis results

Overall, there were 30 studies including 6,801 patients concerning the association between OS and PD-L1 expression. The meta-analysis results show that positive expression was associated with significantly poorer OS compared to the negative expression (HR =1.44, 95% CI =1.18–1.76, $P<0.001$; Table 2 and Figure 2). The heterogeneity among studies was statistically significant ($P<0.001$, $I^2=87.8\%$); therefore, a random-effects model was used.

Three studies with 544 patients reported the RFS. Owing to the significant heterogeneity ($P=0.023$, $I^2=68.5\%$) among these studies, a random-effects model was used. Our results suggested that PD-L1 was not associated with RFS of digestive system cancers (HR =1.27, 95% CI =0.75–2.14, $P=0.368$; Figure 3).

As shown in Table 3 and Figure 4, there were eight studies comprising 1,566 patients which provided results regarding DFS and PD-L1 expression. The pooled data demonstrated that there was no association between them (HR =0.91, 95% CI =0.61–1.37, $P=0.657$, random-effects model).

Subgroup analyses, sensitivity analyses, and meta-regression in OS

To solve the heterogeneity, we performed subgroup analyses by ethnicity, tumor types, and HR estimate. The subgroup analysis by ethnicity suggested a significant association in studies based on Asians (HR =1.50, 95% CI =1.19–1.89, $P=0.001$) but not among other ethnicities (HR =1.07, 95% CI =0.72–1.58, $P=0.740$). In the subgroup analysis by tumor types, significant associations were found in gastric cancer (HR =1.43, 95% CI =1.05–1.94, $P=0.021$) and pancreatic carcinoma (HR =2.64, 95% CI =1.78–3.93, $P<0.001$). For HR estimation, subgroup analysis showed that the overall HR estimate with univariate analysis was 1.64 (95% CI =1.21–2.23, $P=0.001$; Table 2). Meanwhile, it is worth mentioning that heterogeneity among most of the subgroups was statistically significant ($P>0.1$ or $I^2>50\%$).

The included studies were sequentially removed to investigate whether any single study has an influence on the pooled results. As shown in Figure 5, the stable pooled HR was not significantly affected by any individual study.

Figure 1 Flowchart of the selection of the studies in the meta-analysis.
Abbreviation: ELISA, enzyme-linked immunoabsorbent assay.

Table 1 Characteristics of included studies for meta-analyses

First author	Year	Patient source	No of patients	Tumor types	Specimen	Method	PD-L1 expression (%)	Median (range) follow-up (months)	Outcome	M/U	HR (95% CI)	NOS score
Dunne et al ²²	2016	UK	424	CRC	Tissue	IHC	19.8	–	RFS	M	0.76 (0.39–1.45)	7
Wang et al ²⁰	2016	China	262	CRC	Tissue	IHC	20.6	43.5 (21–68)	OS	M	1.90 (0.88–4.14)	7
Yuan et al ¹⁸	2016	China	165	GC	Tissue	IHC	33.9	63.1	OS	U	1.15 (0.80–1.67)	6
Dong et al ²³	2016	China	547	GC	Tissue	IHC	84.8	–	OS	U	0.74 (0.49–1.10)	7
Böger et al ²⁶	2016	Germany	465	GC	Tissue	IHC	23.9	20.7 (0.2–109)	OS	M	0.75 (0.58–0.97)	9
Wang et al ¹⁹	2016	China	105	GC	Tissue	IHC	49.5	42	OS	U	1.93 (1.12–3.32)	8
Chen et al ²⁵	2016	China	536	EC	Tissue	IHC	41.4	32.7 (1.0–88.7)	OS; DFS	M	0.83 (0.59–1.18); 0.80 (0.55–1.17)	9
Chen et al ²⁴	2016	China	162	EC	Tissue	IHC	45	–	OS	U	3.90 (2.51–6.05)	8
Leng et al ²¹	2016	China	106	EC	Tissue	IHC	53.8	55	OS	U	1.39 (0.65–2.99)	7
Lim et al ³¹	2015	Korea	83	Bile duct cancer	Tissue	IHC	68	27–69	DFS	M	0.55 (0.27–1.12)	7
Lim et al ³²	2015	Korea	73	EC	Tissue	IHC	56.2	–	OS; DFS	M	2.29 (1.12–4.69); 1.46 (0.75–2.84)	7
Tamura et al ²⁹	2015	Japan	431	GC	Tissue	IHC	29.7	34	OS	M	1.50 (1.02–2.19)	6
Zhang et al ²⁷	2015	China	132	GC	Tissue	IHC	50.8	66.0 (3.0–153.0)	OS	M	2.70 (1.47–4.95)	8
Qing et al ³⁰	2015	China	107	GC	Tissue	IHC	50.5	42	OS	U	2.01 (1.09–3.70)	7
Eto et al ³⁵	2015	Japan	105	GC	Tissue	IHC	24.8	34 (7–87)	OS; DFS	U	2.26 (0.61–8.33); 1.88 (0.95–3.71)	7
Geng et al ³⁴	2015	China	100	GC	Tissue	IHC	65	>60	OS	M	2.12 (1.59–2.34)	8
Kan and Dong ³³	2015	China	128	HC	Tissue	IHC	82.03	10	OS	U	2.12 (1.32–3.38)	7
Umemoto et al ²⁸	2015	Japan	80	HC	Tissue	IHC	46.3	80	OS; RFS	U	1.27 (0.54–3.01); 1.45 (0.80–2.63)	8
Kim et al ³⁷	2014	Korea	243	GC	Tissue	IHC	56.4	74 (0–123)	OS; DFS	M	0.65 (0.42–1.02); 0.58 (0.37–0.91)	9
Hou et al ³⁸	2014	China	111	GC	Tissue	IHC	63.1	7–48	OS	U	1.47 (0.60–3.57)	9
Liang et al ³⁶	2014	China	185	CRC	Tissue	IHC	55.1	60	OS; DFS	U	0.58 (0.37–0.84); 0.55 (0.36–0.82)	8
Song et al ³⁹	2013	China	347	CRC	Tissue	IHC	–	32.4 (1.2–109.2)	OS	M	1.17 (0.70–1.98)	7
Droeser et al ⁴¹	2013	Switzerland	1,420	CRC	Tissue	IHC	37	–	OS	M	0.92 (0.88–0.96)	6
Shi et al ⁴⁰	2013	China	143	CRC	Tissue	IHC	44.8	–	OS	U	2.61 (1.01–3.58)	8
Loos et al ⁴³	2011	Germany	101	Barrett carcinoma	Tissue	IHC	36.6	75 (7–209)	OS; DFS	U	2.92 (1.50–5.66); 2.99 (1.61–5.64)	8
Zeng et al ⁴²	2011	China	141	HC	Tissue	IHC	51.8	23 (6–36)	OS	M	0.37 (0.19–0.77)	7
Wang et al ⁴⁴	2010	China	81	PC	Tissue	IHC	49.4	24 (8–39)	OS	U	2.56 (1.44–4.56)	6
Gao et al ⁴⁵	2009	China	240	HC	Tissue	IHC	25	–	OS; DFS	U	0.62 (0.40–0.96); 0.56 (0.37–0.85)	8
Chen et al ⁴⁶	2009	China	40	PC	Tissue	IHC	45	58.5 (5–122)	OS; RFS	M	3.23 (1.34–7.80); 4.33 (1.53–12.28)	7
Nomi et al ⁴⁸	2007	Japan	51	PC	Tissue	IHC	39.2	22 (3–91)	OS	U	2.44 (1.22–4.89)	6
Sun et al ⁴⁷	2007	China	92	GC	Tissue	IHC	46.7	6–31	OS	U	2.10 (1.09–4.05)	7
Wu et al ⁴⁹	2006	China	102	GC	Tissue	IHC	42.2	42	OS	U	2.06 (0.99–4.28)	6

Abbreviations: CI, confidence interval; CRC, colorectal cancer; DFS, disease-free survival; EC, esophageal carcinoma; GC, gastric cancer; HC, hepatocellular carcinoma; HR, hazard ratio; IHC, immunohistochemistry; M, multivariate; NOS, Newcastle–Ottawa Scale; OS, overall survival; PC, pancreatic carcinoma; RFS, recurrence-free survival; U, univariate.

Table 2 Main meta-analysis results for OS

Analysis	No of studies	No of patients	Model	HR (95% CI)	P-value	Heterogeneity	
						I ² (%)	P-value
OS	30	6,801	Random	1.44 (1.18–1.76)	0.000	87.8	0.000
Ethnicity							
Asian	27	4,815	Random	1.50 (1.19–1.89)	0.001	82.0	0.000
Non-Asian	3	1,98	Random	1.07 (0.72–1.58)	0.740	85.7	0.001
Tumor types							
CRC	5	2,357	Random	1.15 (0.76–1.72)	0.511	79.7	0.001
GC	13	2,705	Random	1.43 (1.05–1.94)	0.021	83.6	0.000
EC	5	978	Random	1.96 (0.97–3.97)	0.061	88.1	0.000
HC	4	589	Random	0.89 (0.40–1.97)	0.776	86.5	0.000
PC	3	172	Fixed	2.64 (1.78–3.93)	0.00	0.0	0.878
HR estimate							
Multivariate analysis	12	4,190	Random	1.22 (0.92–1.63)	0.171	90.5	0.000
Univariate analysis	18	2,611	Random	1.64 (1.21–2.23)	0.001	80.4	0.000

Note: Bold means that there was significant association between PD-L1 expression and the items of "Analysis".

Abbreviations: CI, confidence interval; CRC, colorectal cancer; EC, esophageal carcinoma; GC, gastric cancer; HC, hepatocellular carcinoma; HR, hazard ratio; OS, overall survival; PC, pancreatic carcinoma.

Figure 2 Forest plot of HR for the association of PD-L1 overexpression and OS.

Note: Weights are from random-effects analysis.

Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival.

Figure 3 Forest plot of HR for the association of PD-L1 overexpression and RFS.

Note: Weights are from random-effects analysis.

Abbreviations: CI, confidence interval; HR, hazard ratio; RFS, recurrence-free survival.

The meta-regression was performed to identify the source of the heterogeneity. We analyzed possible factors including publication year, ethnicity, number of patients, tumor types, and PD-L1 expression. The results confirmed that the number of patients per study might be a major source of heterogeneity (Table 4).

Subgroup analyses in DFS

We also performed subgroup analysis for ethnicity, tumor types, and HR estimate among studies focus on DFS. Only the subgroup analysis for the HR estimate showed a significant association with DFS based on multivariate analysis (HR =0.75, 95% CI =0.59–0.97, $P=0.026$; Table 3).

Publication bias

We performed Begg's and Egger's tests to identify whether any publication bias existed in the published literature in this

meta-analysis. Publication bias was observed among studies reporting OS ($P=0.498$, 0.003), but no publication bias was found among studies reporting DFS ($P=0.230$, 0.330) or RFS ($P=0.308$, 0.328). The Begg's plots for the effect of PD-L1 expression on OS are shown in Figure 6.

Discussion

Recently, according to many reports, cancer cells are able to use immunosuppressive molecules to their advantage via inhibiting antitumor lymphocytes, thus evading destruction by the immune system. Therefore, immunotherapy is now considered a novel method of cancer treatment.⁵⁰ Cancer immunotherapy is a revolutionary cancer treatment targeting the immune checkpoint receptors such as PD-L1. PD-L1 antibodies have been proved to exert clinical activity in more than 15 types of cancers including EC, gastric cancer, hepatocellular cancer, and CRC.⁵¹

Table 3 Main meta-analysis results for DFS

Analysis	No of studies	No of patients	Model	HR (95% CI)	P-value	Heterogeneity	
						I^2 (%)	P-value
DFS	8	1,566	Random	0.91 (0.61–1.37)	0.657	80.1	0.000
Ethnicity							
Asian	7	1,465	Random	0.76 (0.56–1.05)	0.094	64.2	0.010
Non-Asian	1	101	–	0.97 (0.62–1.52)	0.001	–	–
Tumor types							
GC	2	348	Random	1.01 (0.32–3.21)	0.981	87.5	0.005
EC	3	710	Random	1.47 (0.66–3.30)	0.346	84.5	0.002
HR estimate							
Multivariate analysis	4	935	Fixed	0.75 (0.59–0.97)	0.026	49.5	0.115
Univariate analysis	4	631	Random	1.11 (0.50–2.46)	0.805	89.6	0.000

Note: Bold means that there was significant association between PD-L1 expression and the items of "Analysis".

Abbreviations: CI, confidence interval; DFS, disease-free survival; EC, esophageal carcinoma; GC, gastric cancer; HR, hazard ratio.

Figure 4 Forest plot of HR for the association of PD-L1 overexpression and DFS.

Note: Weights are from random-effects analysis.

Abbreviations: CI, confidence interval; DFS, disease-free survival; HR, hazard ratio.

These studies suggested that PD-L1 may be a prognostic biomarker and a potential target of treatment in digestive system cancers. In this meta-analysis, we investigated the association between the expression of PD-L1 and the

prognosis of digestive system cancer patients by analyzing the published data.

Our results showed that PD-L1 overexpression was significantly associated with shorter OS. These results indicated

Figure 5 Sensitivity analysis of pooled HRs on the association between PD-L1 expression and OS.

Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival.

Table 4 Meta-regression analyses of potential source of heterogeneity

Heterogeneity factors	Coefficient	SE	Z	P-value	95% CI	
					LL	UL
Publication year	-0.024	0.038	-0.63	0.536	-0.102	0.054
Ethnicity	-0.246	0.351	-0.70	0.489	-0.966	0.473
Number of patients	-0.001	0.000	-2.33	0.028	-0.002	-0.000
Tumor types	0.089	0.094	0.94	0.353	-1.039	0.282
PD-L1 expression	0.001	0.008	0.08	0.938	-0.015	0.016

Abbreviations: CI, confidence interval; LL, lower limit; SE, standard error; UL, upper limit.

that PD-L1 can serve as a novel parameter for prognostication and a promising target for anticancer therapy in digestive system cancers. When extended to subgroup analysis, no clear correlation between PD-L1 expression and OS was found in non-Asian, CRC, EC, and hepatocellular carcinoma (HC) patients, possibly owing to the insufficiently large sample size. Therefore, it is necessary for better designed studies with more patients to prove or to retort our results in the future.

There was a significant heterogeneity across the included studies. However, subgroup analyses of ethnicity, tumor types, and the methods used to estimate the HR failed to identify its source. The sensitivity analyses showed that the stable pooled HR was not significantly affected by each individual study. The meta-regression confirmed that the number of patients might be a major source of heterogeneity. However, the meta-regression adjusted R^2 value of the number of patients is just 15.78% (data not shown), which could only explain a small part of heterogeneity source. Therefore, it is likely that the heterogeneity is due to the differences in the baseline characteristics of patients, the immunohistochemical methods, and the baseline referring to positive/high PD-L1 expression. However, because of lacking clinical data in

these aspects, we cannot determine their contribution to the heterogeneity among studies.

Previously, some meta-analyses have been conducted to study the association between PD-L1 and some cancers in the digestive system. Huang et al⁵² identified nine studies that involved 2,500 gastrointestinal tract cancer patients, and reported that PD-L1 is a prognostic risk factor for gastrointestinal tract cancer. The study by Wu et al,⁵³ which included seven studies with 687 patients, showed that positive PD-L1 expression status in tumor cells was associated with worse 5-year OS of EC, gastric cancer, and CRC. Compared with these studies, our meta-analysis has some differences and advantages. First of all, our study is the first meta-analysis to estimate the role of PD-L1 in the prognosis of digestive system cancers. Second, we not only analyzed OS but also evaluated DFS and RFS, which contributed to a comprehensive understanding of the issue. Third, our conclusion is more reliable because several new studies fulfilling the inclusion criteria have been included.

We attempted to conduct a comprehensive analysis of PD-L1 and prognosis of digestive system cancers, but it should be recognized that there are still some limitations in our study. First, some survival data were not reported directly; therefore, an indirect method was used to extract data from the Kaplan–Meier survival curves, which may affect the accuracy of the original data. Second, publication bias was observed among studies reporting OS. The reason may be that studies with positive results were published more easily. Third, we cannot recognize the association between subgroups of RFS and PD-L1 expression due to lack of data. More importantly, the PD-L1 expression level measured using immunohistochemistry might show high variability between studies. Hence, a baseline for positive/high PD-L1 expression should be established.

Conclusion

We found that PD-L1 expression indicated poor OS outcomes. We indicated that PD-L1 may serve as a prognostic

Figure 6 Funnel plots of publication bias for all the included studies reported with OS.

Abbreviations: HR, hazard ratio; OS, overall survival; SE, standard error.

indicator and a potential novel target for treatment in digestive system cancers.

Acknowledgments

This study was supported by the National Natural Science Foundation, China (No 81471670); China Postdoctoral Science Foundation (No 2014M560791; 2015T81037); the Fundamental Research Funds for the Central Universities, China (No 2014qngz-04); the International Cooperative Project of Shaanxi province, People's Republic of China (No 2014KW-23-07), and Science and Technology Plan of Innovation Project, Shaanxi province, China (No 2015KTCL03-06). The authors thank all the nonauthor contributors: Yi Zhen, Yujiao Deng, and Zhe Dou.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin*. 2016;66(1):7–30.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin*. 2010;60(5):277–300.
3. Mohammed F. Esophageal cancer. *N Engl J Med*. 2004;350(13):1363–1364; author reply 1363–1364.
4. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. *Clin Cancer Res*. 2013;19(5):1021–1034.
5. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. *J Clin Oncol*. 2015;33(17):1974–1982.
6. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. *Cancer Med*. 2013;2(5):662–673.
7. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. *Nat Rev Immunol*. 2008;8(6):467–477.
8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012;12(4):252–264.
9. Chen J, Li G, Meng H, et al. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. *Cancer Immunol Immunother*. 2012;61(1):101–108.
10. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med*. 2002;8(8):793–800.
11. Lote H, Cafferkey C, Chau I. PD-1 and PD-L1 blockade in gastrointestinal malignancies. *Cancer Treat Rev*. 2015;41(10):893–903.
12. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat Med*. 1998;17(24):2815–2834.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177–188.
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst*. 1959;22(4):719–748.
15. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI; Health Outcomes, Policy, and Economics (HOPE) Collaborative Group. Understanding heterogeneity in meta-analysis: the role of meta-regression. *Int J Clin Pract*. 2009;63(10):1426–1434.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629–634.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. 1994;50(4):1088–1101.
18. Yuan J, Zhang J, Zhu Y, et al. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance. *Oncotarget*. 2016;7(26):39671–39679.
19. Wang LA, Wei X, Li Q, Chen L. The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography. *Tumour Biol*. 2016;37(6):7327–7332.
20. Wang L, Ren F, Wang Q, et al. Significance of programmed death ligand 1 (PD-L1) immunohistochemical expression in colorectal cancer. *Mol Diagn Ther*. 2016;20(2):175–181.
21. Leng C, Li Y, Qin J, et al. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8(+) T cells. *Oncol Rep*. 2016;35(2):699–708.
22. Dunne PD, McArt DG, O'Reilly PG, et al. Immune-derived PD-L1 gene expression defines a subgroup of stage II/III colorectal cancer patients with favorable prognosis who may be harmed by adjuvant chemotherapy. *Cancer Immunol Res*. 2016;4(7):582–591.
23. Dong M, Wang HY, Zhao XX, et al. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma. *Hum Pathol*. 2016;53:25–34.
24. Chen MF, Chen PT, Chen WC, Lu MS, Lin PY, Lee KD. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. *Oncotarget*. 2016;7(7):7913–7924.
25. Chen K, Cheng G, Zhang F, et al. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. *Oncotarget*. 2016;7(21):30772–30780.
26. Böger C, Behrens HM, Mathiak M, Kruger S, Kalthoff H, Rocken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. *Oncotarget*. 2016;7(17):24269–24283.
27. Zhang L, Qiu M, Jin Y, et al. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. *Int J Clin Exp Pathol*. 2015;8(9):11084–11091.
28. Umamoto Y, Okano S, Matsumoto Y, et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. *J Gastroenterol*. 2015;50(1):65–75.
29. Tamura T, Ohira M, Tanaka H, et al. Programmed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer. *Anticancer Res*. 2015;35(10):5369–5376.
30. Qing Y, Li Q, Ren T, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. *Drug Des Devel Ther*. 2015;9:901–909.
31. Lim YJ, Koh J, Kim K, et al. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. *Radiother Oncol*. 2015;117(1):165–170.
32. Lim SH, Hong M, Ahn S, et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. *Eur J Cancer*. 2016;52:1–9.
33. Kan G, Dong W. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology. *Eur Rev Med Pharmacol Sci*. 2015;19(16):3063–3071.
34. Geng Y, Wang H, Lu C, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. *Int J Clin Oncol*. 2015;20(2):273–281.
35. Eto S, Yoshikawa K, Nishi M, et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. *Gastric Cancer*. 2016;19(2):466–471.
36. Liang M, Li J, Wang D, et al. T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China's Heilongjiang province. *Tumour Biol*. 2014;35(1):55–60.
37. Kim JW, Nam KH, Ahn SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. *Gastric Cancer*. 2016;19(1):42–52.

38. Hou J, Yu Z, Xiang R, et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. *Exp Mol Pathol*. 2014;96(3):284–291.
39. Song M, Chen D, Lu B, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. *PLoS One*. 2013;8(6):e65821.
40. Shi SJ, Wang LJ, Wang GD, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. *PLoS One*. 2013;8(10):e76012.
41. Drieser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. *Eur J Cancer*. 2013;49(9):2233–2242.
42. Zeng Z, Shi F, Zhou L, et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. *PLoS One*. 2011;6(9):e23621.
43. Loos M, Langer R, Schuster T, et al. Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma. *Ann Thorac Surg*. 2011;91(4):1025–1031.
44. Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. *World J Surg*. 2010;34(5):1059–1065.
45. Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. *Clin Cancer Res*. 2009;15(3):971–979.
46. Chen XL, Yuan SX, Chen C, Mao YX, Xu G, Wang XY. [Expression of B7-H1 protein in human pancreatic carcinoma tissues and its clinical significance]. *Ai Zheng*. 2009;28(12):1328–1332. Chinese.
47. Sun J, Xu K, Wu C, et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. *Tissue Antigens*. 2007;69(1):19–27.
48. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. *Clin Cancer Res*. 2007;13(7):2151–2157.
49. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. *Acta Histochem*. 2006;108(1):19–24.
50. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. *Nature*. 2011;480(7378):480–489.
51. Sharma P, Allison JP. The future of immune checkpoint therapy. *Science*. 2015;348(6230):56–61.
52. Huang B, Chen L, Bao C, et al. The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis. *Oncotargets Ther*. 2015;8:2617–2625.
53. Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. *PLoS One*. 2015;10(6):e0131403.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress